Amgen beat Wall Street expectations in Q1 2026 with $8.62 billion in revenue and $5.15 EPS, driven by strong growth in key drugs like Repatha and Evenity. Management raised full-year revenue and EPS ...

Amgen AMGN reported first-quarter adjusted earnings of $5.15 per share, which beat the Zacks Consensus Estimate of $4.73 per ...

Amgen has launched a late-stage program to test the feasibility of switching patients from weekly GLP-1 injections to its own ...